Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.
Teh-Liane
TL
Khoo
Alberto
A
Catalano
Shane
S
Supple
Li
L
Chong
Sue-Ching
SC
Yeoh
Stephen
S
Yeung
Harry
H
Iland
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001483:Base Sequence; D001549:Benzamides / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D014644:Genetic Variation; D006579:Heterozygote; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced*; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D021362:Palate, Hard / Q000473:pathology*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D000090063:Proto-Oncogene Mas; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; C000715470:MAS1 protein, human; D010879:Piperazines; D000090063:Proto-Oncogene Mas; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit